2024, Chemotherapy and Specialty Pharmacies

Q&A: How IQVIA Keeps Pharmacists Engaged with US Prescription Drug Use

Drug Topics

JULY 14, 2025

Dynamics that have become apparent during 2024 have driven significant revisions to the outlook, and in this report, the drivers of change in medicine spending over the next 5 years are deconstructed to enable better understanding,” wrote IQVIA. There [were] up to 48 novel drugs launched in the US in 2024; 31 of them were orphan drugs.

Immunization

Immunization Compounding Specialty Pharmacies Independent Pharmacies

Pharmacist’s Role Expands in the Era of Cannabis Rescheduling

Drug Topics

AUGUST 12, 2025

The FDA’s report to the DEA stated there is good evidence of the possible utility for personalizing treatment plans to treat nausea and vomiting secondary to chemotherapy, pain, and appetite disorders. November 18, 2024. doi:10.1136/heartjnl-2024-325429. StatPearls Publishing; 2024. Updated November 2019. 2022.12.022 7.

Specialty Pharmacies

Specialty Pharmacies Patient Care Independent Pharmacies Compounding

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

Pharmacy Times

JULY 16, 2025

14,15 Lung Cancer Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post Progression Tarlatamab has shown promising efficacy in relapsed SCLC based on the initial single-arm trial findings, leading to an FDA approval in 2024, but challenges with administration have limited its widespread adoption.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Compounding Pharmacies Immunization Chemotherapy

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

JUNE 27, 2025

Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. 5 Phase 3 ECHO Trial: A New Frontline Option The approval was supported by data from the phase 3 ECHO trial (NCT02972840), presented at the 2024 European Hematology Association Hybrid Congress. June 21, 2024. Hemasphere.

FDA

FDA Compounding Pharmacies Immunization Chemotherapy

Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment

Pharmacy Times

JUNE 9, 2025

Presented at: American Society of Health-System Pharmacists 2025 Pharmacy Futures. 2024 Global Strategy for Asthma Mnagement and Prevention Guidelines. doi:10.1056/NEJMoa1901963 Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Compounding Pharmacies

Compounding Pharmacies Hospitals Immunization Chemotherapy

Evaluation of a Pharmacy-Delivered Oncofertility Intervention

Pharmacy Times

JUNE 11, 2025

Image Credit: © Chinnapong - stock.adobe.com At the 2025 Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025, an encore presentation from the Pacific Coast Reproductive Society Annual Meeting will highlight findings from a retrospective analysis conducted by Walgreens Specialty Pharmacy.

Specialty Pharmacies

Specialty Pharmacies Compounding Pharmacies Immunization Chemotherapy

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

Pharmacy Times

JUNE 17, 2025

Prior to the start of OPC on June 19, participants are invited to attend the Hematology/Oncology Pharmacy Association (HOPA) BCOP Program in person on June 18. HOPA has selected 4.0 Additional information is available here.

Mail-Order Pharmacies

Mail-Order Pharmacies Compounding Pharmacies Medical Records Dosage

How AI Brings Pharmacogenetics to the Frontline of Precision Medicine

Pharmacy Times

JULY 22, 2025

A man aged 55 years with metastatic colorectal cancer was initiated on a standard fluoropyrimidine-based chemotherapy regimen. billion in July 2024. Within a week, he developed severe neutropenia, gastrointestinal shutdown, and septic complications requiring admission to the intensive care unit.

Compounding Pharmacies

Compounding Pharmacies FDA Hospitals Immunization

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Pharmacy Times

JUNE 16, 2025

Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. A 67% FN rate difference between pegfilgrastim and filgrastim was observed in patients with transportation barriers.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Chemotherapy Compounding Pharmacies Immunization

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

JUNE 20, 2025

August 8, 2024. Updated January 19, 2024. LinkedIn Workplace Learning Report 2024. American Oncology Network. Accessed May 15, 2025. How your oncology peers manage the complexities of care. Oncology Live ®. December 13, 2018. Accessed May 15, 2025. Desimone R. Improve work performance with a focus on employee development.

Compounding

Compounding Compounding Pharmacies Patient Care Immunization

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

Pharmacy Times

JUNE 19, 2025

The field is expanding into autoimmune diseases, with nononcology trials representing 51% of the pipeline by late 2024. Development Trends: Oncology at the Forefront Gene therapy currently ranks third among therapeutic focus areas, with 2151 compounds in development in 2024 ( Figure ).

Compounding

Compounding Compounding Pharmacies FDA Immunization

Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

Pharmacy Times

JUNE 17, 2025

Conclusions We demonstrated the feasibility of leveraging a complex EHR data source from an integrated health system to study the impact of dose modifications on clinical outcomes for self-administered chemotherapy. Nearly half of the patients with CML on imatinib experienced dosage modifications in this study. HOPA has selected 4.0

Dosage

Dosage Compounding Pharmacies Immunization Chemotherapy

Investigating the Pharmacist’s Role in Psychedelic-Assisted Psychotherapy for Patients With Cancer

Pharmacy Times

JUNE 27, 2025

After learning of his diagnosis, our relationship shifted from small talk at school events to detailed discussions in an infusion center setting about chemotherapy, immunotherapy, clinical trials, alternative medicines, and anticipated adverse effects. Pharmacy Times. January 17, 2024. 2024;25(1):336. Accessed May 16, 2025.

Compounding Pharmacies

Compounding Pharmacies Immunization Chemotherapy Hospitals

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Pharmacy Times

JUNE 11, 2025

Additionally, patients may have received prior chemotherapy for advanced disease. In TRUST-II, treatment with taletrectinib achieved a cORR of 62%, and as of October 2024 (the time of data cut-off), the median DOR was 19.4 Updated November 21, 2024. months with a median follow-up of 19 months. Updated October 30, 2023.

FDA

FDA Compounding Pharmacies Immunization Hospitals

Anlotinib Following Benmelstobart Plus Chemotherapy Improves Progression-Free Survival in S-NSCLC

Pharmacy Times

JUNE 25, 2025

Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. months versus 7.79 months with tislelizumab.

Chemotherapy

Chemotherapy Compounding Pharmacies Immunization Hospitals

Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia

Pharmacy Times

JUNE 18, 2025

Prior to the start of OPC on June 19, participants are invited to attend the Hematology/Oncology Pharmacy Association (HOPA) BCOP Program in person on June 18. HOPA has selected 4.0 Additional information is available here.

Compounding Pharmacies

Compounding Pharmacies Dosage Immunization Hospitals

Efficacy and Safety in CPX-351 vs 7+3 in Adults Younger Than 60 Years With AML-MRC or t-AML

Pharmacy Times

AUGUST 7, 2025

Methods Patients aged 18 to 59 years with t-AML or AML-MRC treated with CPX-351 or 7+3 as induction chemotherapy between 2015 and 2022 at 3 National Cancer Institute–designated cancer centers were included. The primary outcome was the incidence of CR or CRi after induction chemotherapy. Author Disclosures Brian A.

Chemotherapy

Chemotherapy FDA Hospitals Immunization

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

Pharmacy Times

JUNE 19, 2025

1 Biomarker testing is relatively new in the treatment landscape for NSCLC but has proven incredibly important for personalizing patient care, transforming from a generic chemotherapy approach to a highly personalized, genomically driven treatment strategy. For advanced disease, chemotherapy was the standard.

Chemotherapy

Chemotherapy Compounding Pharmacies Hospitals Immunization

Real-World Data Suggests Cannabis Use is Associated With Major Adverse Cardiovascular Events

Pharmacy Times

JUNE 25, 2025

doi:10.1136/heartjnl-2024-325429. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Storck W, Elbaz M, Vindis C, Déguilhem A, Lapeyre-Mestre M, Jouanjus E. 2025;0:1–10. CNN Health. Updated June 18, 2025. Subscribe Now!

Compounding Pharmacies

Compounding Pharmacies Immunization Chemotherapy Hospitals

Clinical Manifestations of Acute, Chronic Graft-vs-Host Disease With PTCy in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

Pharmacy Times

JUNE 18, 2025

Prior to the start of OPC on June 19, participants are invited to attend the Hematology/Oncology Pharmacy Association (HOPA) BCOP Program in person on June 18. HOPA has selected 4.0 Additional information is available here.

Compounding Pharmacies

Compounding Pharmacies Dosage Immunization Hospitals

FDA Approves Datopotamab for Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

Pharmacy Times

JUNE 23, 2025

Datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc) received FDA approval for treatment of adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. December 9, 2024. Pharmacy Times.

FDA

FDA Compounding Pharmacies Chemotherapy Immunization

Five for Friday November 1: Celebrating Success in Advancing Medication Use Quality

PQA

NOVEMBER 1, 2024

We are excited to host members next week at the 2024 PQA Leadership Summit and PQA Convenes: Quality Medication Use in Rare Disease at the Renaissance Arlington Capital View Hotel in Arlington, Va. This year's summit will focus on PQA's recent and ongoing work to develop standard pharmacy quality measures.

Specialty Pharmacies

Specialty Pharmacies Vaccines Chemotherapy Immunization

Pharmacy Technician Pulse

Q&A: How IQVIA Keeps Pharmacists Engaged with US Prescription Drug Use

Pharmacist’s Role Expands in the Era of Cannabis Rescheduling

Trending Sources

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment

Evaluation of a Pharmacy-Delivered Oncofertility Intervention

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

How AI Brings Pharmacogenetics to the Frontline of Precision Medicine

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

Investigating the Pharmacist’s Role in Psychedelic-Assisted Psychotherapy for Patients With Cancer

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Anlotinib Following Benmelstobart Plus Chemotherapy Improves Progression-Free Survival in S-NSCLC

Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia

Efficacy and Safety in CPX-351 vs 7+3 in Adults Younger Than 60 Years With AML-MRC or t-AML

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

Real-World Data Suggests Cannabis Use is Associated With Major Adverse Cardiovascular Events

Clinical Manifestations of Acute, Chronic Graft-vs-Host Disease With PTCy in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

FDA Approves Datopotamab for Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

Five for Friday November 1: Celebrating Success in Advancing Medication Use Quality

Stay Connected